Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.20-0.16 (-2.17%)
At close: 04:00PM EDT
7.28 +0.08 (+1.11%)
After hours: 06:45PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close7.36
Open7.54
Bid5.78 x 1000
Ask8.93 x 800
Day's Range7.12 - 7.54
52 Week Range5.61 - 13.45
Volume192,662
Avg. Volume77,354
Market Cap469.159M
Beta (5Y Monthly)0.32
PE Ratio (TTM)378.95
EPS (TTM)0.02
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AMYT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amryt Pharma plc
    Daily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

    Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® recently approved by the European Commission for the treatment of EB DUBLIN, Ireland, and Boston MA, June 24, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the company plans to submit a Formal Dispute Resolution Request (FDRR) for the company’s New Drug Application (NDA

  • GlobeNewswire

    European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

    European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA, June 23, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the European Commission (EC) approval of Filsuvez® in the European Union (EU) for the treatment of parti

  • GlobeNewswire

    Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

    Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 Data from the MPOWERED OLE and first presentation of open-label extension (OLE) data from 2nd year of OPTIMAL demonstrate the long-term safety and efficacy profile of Mycapssa® DUBLIN, Ireland, and Boston MA, June 13, 2022 - Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, pre

Advertisement
Advertisement